TETRAPHARM Appoints Rolf Sass Sørensen

TETRAPHARM announced a leadership change on October 9, 2026. TETRAPHARM appointed Rolf Sass Sørensen, formerly of Bavarian Nordic, as CEO to succeed co-founder Martin Rose and lead the Danish biopharmaceutical company’s continued development.

What changed

Rolf Sass Sørensen was named Chief Executive Officer. Sørensen succeeds Martin Rose, who founded the company with Jesper Breum in 2018, and Rose and Breum are leaving their operational roles to pursue new biotech ventures together while remaining shareholders in TETRAPHARM.

Leader: Rolf Sass Sørensen
Role: Chief Executive Officer
Effective: October 6, 2026
Announcement date: October 9, 2026

Leadership background

Sørensen brings more than 30 years of experience, including senior roles in investor relations and corporate communications. He was previously Vice President Investor Relations and Communications at Bavarian Nordic. The company said he has extensive knowledge of the life sciences sector and of the relationship between biotechnology companies and capital markets.

The mandate

TETRAPHARM said Sørensen will work with the Board of Directors and the organization to lead the company’s continued development as it advances its novel drug molecules and proprietary drug delivery technologies alongside its contract development and manufacturing services. Sørensen said his responsibility, together with the team, is to translate the company’s potential into clear priorities and measurable progress.

Why this matters for GTM teams

Executive appointments can precede changes in strategy, operating cadence, hiring, partnerships, and technology priorities. The useful signal is not the title alone: teams should watch the new leader’s stated mandate, prior playbook, organizational scope, and the initiatives announced during the first two quarters.

Source and methodology

This leadership profile is based on the company’s announcement. Roles, transition timing, and biographical details are presented as announced; SalesTools Research does not infer undisclosed succession plans.

TETRAPHARM